QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Bioceres Crop Solutions Corp. (BIOX)

Basic Materials

No action
Fundamental
1
Sentiment
1
Technical
1

Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3 (auditor going-concern and note-acceleration distress — hard blocks on any bullish entry), and the technical gates independently fail: 20-day avg dollar volume $231,905 vs the $5M floor, recent 3-session avg $150,154 vs the $1.5M floor, and max overnight gap 8.49% vs the 5% cap. No pullback/oversold limit qualifies (countertrend under a declining SMA200 without a momentum reclaim) and no breakout stop qualifies (R/R 0.68 at the nearest settled high 0.4299, foreclosed by the gap/liquidity blocks).

Analysis as of 2026-09-20· more than 2 trading days ago

Company overview

Bioceres Crop Solutions Corp. enhances agricultural output through seed technologies, crop protection products, and crop nutrition solutions. It operates in Argentina, Uruguay, France, and South Africa, focusing on drought-resistant seed technology and specialized fertilizers. The company is a subsidiary of Bioceres LLC.

Fundamental

very weak
Fundamental1
Distressed fundamentals

Bioceres Crop Solutions is in financial distress with unresolved going-concern issues and significant debt challenges.

Bioceres Crop Solutions is in deep financial distress. The FY2025 20-F carries an auditor going-concern opinion that remains unresolved, US$118.6M of secured notes have been accelerated and are in litigation after the January 2026 foreclosure of the Pro Farm unit, and roughly US$12M of cash stands against about US$226M of financial debt. Continuing revenue fell 18% in fiscal 2026 and the ongoing business still loses money (about US$54.4M) before the US$179.4M non-cash foreclosure charge, while interest expense of US$33.5M exceeds adjusted EBITDA of US$25.5M. Earnings are negative, EV/EBITDA is around 93x, both DCF models produce negative per-share values, Altman Z sits near 0.37 in the distress zone, and Nasdaq delisting risk lingers with a possible reverse split. The equity is a speculative, high-risk claim with no dividend support and no bullish insider signal; this reads as a Do Nothing / watchlist situation until the capital-structure litigation and refinancing are resolved.

Sentiment

very weak
Sentiment1
Negative sentiment

Media sentiment is negative, retail engagement is absent, and no positive catalysts are identified.

Dominant catalyst is the bearish Q4/FY2026 earnings print of 2026-09-14 (announced confidence; Q4 EPS -$0.50 vs -$0.06 consensus with the stock slipping in extended trading), compounded by the US$118.6M accelerated-notes dispute and the Nasdaq Capital Market transfer; sentiment delta is indeterminate (sparse 30-90d baseline with only 2 generic sector items); severe red-flag cap applied - going-concern/auditor doubt with unresolved covenant breaches and no disclosed refinancing path.

Technical

very weak
Technical1
Strong downtrend

The stock is in a strong downtrend with poor liquidity and no reversal signals.

Bearish/broken structure. Price 0.3603 is below SMA20 0.42, SMA50 0.39, SMA200 0.64, EMA9 0.40, EMA21 0.41 and every fast average; ADX14 30.1 (>25) with price under all MAs marks a strong DOWN-trend, not bullish; MACD line 0.00 under signal 0.01 with histogram -0.01 (negative, weakening); RSI 37.7 weak, Williams %R -92.5 deeply oversold with no reversal confirmation; three straight down sessions (-5.4%, -5.8%, -9.9%) on expanding downside volume. ATR14 0.04 = 11.1% of price and a max overnight gap of 8.49% make any stop unprotectable; 20-day liquidity $231,905 is far below the $5M floor. Technical score 1. Trade suppressed regardless: fundamentalScore 1 and qualitativeScore 1 are both below the floor of 3.

You’re looking at 2026-09-20 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.